The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

This podcast episode explores the discovery and development of GLP-1-based drugs, with a focus on the work of Novo Nordisk. Lotte Bjerre Knudsen, Chief Scientific Advisor of Novo Nordisk, shares her insights on the scientific journey behind the development of these drugs for the treatment of diabetes and obesity. The episode highlights the challenges and strategies involved in the research and development process, the importance of collaboration and perseverance, and the impact of innovative thinking and the unique work culture at Novo Nordisk.

Outlines

Sign in to continue reading, translating and more.

Open full episode in Podwise

ACQ2 by Acquired

Lotte's Journey to Novo Nordisk and the Discovery of GLP-1

From Laundry Detergent Enzymes to GLP-1 Research: An Unlikely Journey

GLP-1: From Discovery to Drug Development

Novo Nordisk's Insulin Expertise and the Creation of Linacrotoid

GLP-1's Dual Effects: Diabetes and Obesity Treatment from the Beginning

Novo Nordisk's Journey in Obesity Treatment: From Loneliness to Leadership

The Power of Persistence and Collaboration in Obesity Drug Development

The Fatty Acid Platform Technology: A Key to Novo Nordisk's Success

GLP-1: How it Works from Injection to Weight Loss

GLP-1's Role in Weight Loss: Peripheral vs. Central Effects

GLP-1's Long-Acting Formula: A Surprising Discovery in Weight Loss

The Iterative Process of Pharmaceutical Development: From 4,000 Molecules to Semaglutide

Scandinavian Work Culture: Challenging Authority and Pursuing Innovation

The Power of Perseverance and Relatability in Innovation

The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

ACQ2 by Acquired

00:00Lotte's Journey to Novo Nordisk and the Discovery of GLP-1

Lotte's Journey to Novo Nordisk and the Discovery of GLP-1

02:03From Laundry Detergent Enzymes to GLP-1 Research: An Unlikely Journey

From Laundry Detergent Enzymes to GLP-1 Research: An Unlikely Journey

07:30GLP-1: From Discovery to Drug Development

GLP-1: From Discovery to Drug Development

11:07Novo Nordisk's Insulin Expertise and the Creation of Linacrotoid

Novo Nordisk's Insulin Expertise and the Creation of Linacrotoid

15:31GLP-1's Dual Effects: Diabetes and Obesity Treatment from the Beginning

GLP-1's Dual Effects: Diabetes and Obesity Treatment from the Beginning

19:55Novo Nordisk's Journey in Obesity Treatment: From Loneliness to Leadership

Novo Nordisk's Journey in Obesity Treatment: From Loneliness to Leadership

24:38The Power of Persistence and Collaboration in Obesity Drug Development

The Power of Persistence and Collaboration in Obesity Drug Development

29:12The Fatty Acid Platform Technology: A Key to Novo Nordisk's Success

The Fatty Acid Platform Technology: A Key to Novo Nordisk's Success

33:14GLP-1: How it Works from Injection to Weight Loss

GLP-1: How it Works from Injection to Weight Loss

38:41GLP-1's Role in Weight Loss: Peripheral vs. Central Effects

GLP-1's Role in Weight Loss: Peripheral vs. Central Effects

43:37GLP-1's Long-Acting Formula: A Surprising Discovery in Weight Loss

GLP-1's Long-Acting Formula: A Surprising Discovery in Weight Loss

48:12The Iterative Process of Pharmaceutical Development: From 4,000 Molecules to Semaglutide

The Iterative Process of Pharmaceutical Development: From 4,000 Molecules to Semaglutide

51:32Scandinavian Work Culture: Challenging Authority and Pursuing Innovation

Scandinavian Work Culture: Challenging Authority and Pursuing Innovation

55:59The Power of Perseverance and Relatability in Innovation

The Power of Perseverance and Relatability in Innovation